Drug
Lacutoclax clinical trials
Also written LP-108.
- studies test it
- 5
- open now
- 3
- in phase 3
- 0
- first study started
- 2020
Keep track of what changes. Save the lacutoclax studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2023 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 1
Guangzhou Lupeng Pharmaceutical Company LTD. (3) · Newave Pharmaceutical Inc (1) · The First Affiliated Hospital with Nanjing Medical University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses lacutoclax is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingPhase 1Guangzhou Lupeng Pharmaceutical Company LTD.NCT05641259Written as LP-108
- A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07609823Written as Lacutoclax
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingPhase 1/2Guangzhou Lupeng Pharmaceutical Company LTD.NCT07609862Written as Lacutoclax+Rocbrutinib
- Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AMLCompletedPhase 1Newave Pharmaceutical IncNCT04139434Written as LP-108
- A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell LymphomaStatus unknownPhase 1The First Affiliated Hospital with Nanjing Medical UniversityNCT04356846Written as LP-108 tablet
Codes
What other systems call lacutoclax · ClinicalTrials.gg INT017597
- UNII (FDA) PMG5245L91LACUTOCLAXOne source FDA
- NCI Thesaurus C203075LacutoclaxOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PMG5245L91 | LACUTOCLAX | One source FDA |
| NCI Thesaurus | C203075 | Lacutoclax | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.